The short version of HPLC-MS fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-13 and is reviewed periodically as new material appears.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water; stock solutions use organic solvent. |
| Storage | -20°C, desiccated, protected from light | Limits hydrolysis and photodegradation. |
| Analytical method | HPLC-UV/MS | Used for identity and purity assessment. |
| Synonyms | SR9009, Stenabolic | Naming varies by supplier. |
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
This relationship between the half-life and the decay constant shows that highly radioactive substances are quickly spent, while those that radiate weakly endure longer. Half-lives of known radionuclides vary by almost 54 orders of magnitude, from more than 2.25(9)×1024 years (6.9×1031 sec) for the very nearly stable nuclide 128Te, to 8.6(6)×10−23 seconds for the highly unstable nuclide 5H. The factor of ln(2) in the above relations results from the fact that the concept of "half-life" is merely a way of selecting a different base other than the natural base e for the lifetime expression. The time constant τ is the e −1 -life, the time until only 1/e remains, about 36.8%, rather than the 50% in the half-life of a radionuclide. Thus, τ is longer than t1/2. The following equation can be shown to be valid:
K2CO3 + CO2 + H2O → 2 KHCO3 CO2 de-scrubber: The above potassium carbonate solution (enriched with CO2) is then sent to the CO2 de-scrubber where CO2 is de-scrubbed by stepwise (usually two steps) flashing. The first step is done to remove the hydrocarbon gases, and the second step is employed to strip off CO2.
In eukaryotes, oxidative phosphorylation occurs in the mitochondrial cristae. It comprises the electron transport chain that establishes a proton gradient (chemiosmotic potential) across the boundary of the inner membrane by oxidizing the NADH produced from the Krebs cycle. ATP is synthesized by the ATP synthase enzyme when the chemiosmotic gradient is used to drive the phosphorylation of ADP. The electrons are finally transferred to exogenous oxygen and, with the addition of two protons, water is formed.
Sources: en.wikipedia.org
University of Western Ontario (LL.D.) on May 30, 1924 University of Toronto (D.Sc.) in 1924 Queen's University (LL.D.) in 1924 University of Michigan (LL.D.) in 1924 Yale University (D.Sc.) in 1924 University of the State of New York (D.Sc.) in 1931 McGill University (D.Sc.) in 1939
The Cats went 21–1 to claim the McClelland Trophy four games ahead of their nearest challenger, Hawthorn. After relatively easy wins against St Kilda and the Western Bulldogs in the finals, Geelong under Thompson were into their second straight grand final, this time against Hawthorn, and were again hot favourites. In an upset, though, Hawthorn beat Geelong under Thompson by 26 points in front of 100,012 fans in the 2008 AFL Grand Final. During an end-of-season holiday to New York that year, Thompson ran into Melbourne Storm coach Craig Bellamy whilst inside a hotel. They were said to have drowned their sorrows following their respective Grand Final losses (Bellamy's Melbourne Storm lost the 2008 NRL Grand Final to Manly). In the 2009 season, following a heartbreaking loss to Hawthorn in the 2008 Grand Final Premiership decider, Geelong under Thompson compiled an 18–4 record during the minor round and disposed of the Western Bulldogs and then Collingwood during the finals series. On 26 September 2009 in the 2009 AFL Grand Final, Geelong under Thompson faced a St Kilda side determined to break its 43-year Premiership drought. In front of 99,251 fans on a rain-soaked MCG deck, the Cats under Thompson clawed their way back after trailing at every break to win the AFL premiership by 12 points. This would be Geelong's second flag under Thompson in three years cementing their place as one of the great teams of the modern era. Thompson as always was magnanimous in victory and accepted the AFL Premiership trophy alongside Geelong legend Bob Davis.
=== Topical === Throughout clinical trials, data from a limited number of exposed pregnancies indicate that there is no clinical evidence that treatment with eflornithine adversely affects pregnant women or fetuses.
Sources: en.wikipedia.org
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.
The solid is generally kept cold, dry, and protected from light. Solutions are often frozen in single-use aliquots to reduce repeated freeze-thaw cycles.
It indicates a material sold for laboratory study, not for human use. The label does not guarantee pharmaceutical purity, sterility, or regulatory approval.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.